Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LCK | P06239 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.31 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588367 | 0.90 | CA9 (0.41) | CA9CRBNDDB1TRPV1PARP1 | |
| SCHEMBL3605984 | 0.89 | TRPV1 (0.39) | CA9CRBNDDB1TRPV1 | |
| SCHEMBL3603350 | 0.86 | TRPV1 (0.42) | CA9LCKCRBNTRPV1 | |
| SCHEMBL3600255 | 0.85 | TRPV1 (0.31) | CRBNDDB1TRPV1PARP1CHEK1 | |
| SCHEMBL3601169 | 0.84 | CA9 (0.37) | CA9CRBNDDB1CYP19A1KDM4E | |
| SCHEMBL3598578 | 0.80 | RET (0.35) | CA9CRBNCYP19A1KDM4EMEN1 | |
| SCHEMBL3602382 | 0.79 | TRPV1 (0.45) | CA9CRBNDDB1TRPV1KDM4E | |
| SCHEMBL3588363 | 0.77 | TRPV1 (0.36) | CRBNDDB1TRPV1PARP1CHEK1 | |
| SCHEMBL3598181 | 0.77 | TRPV1 (0.47) | CA9CRBNTRPV1KDM4EMEN1 | |
| SCHEMBL3597785 | 0.76 | PDE3B (0.36) | CA9CRBNDDB1PARP1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | CA9 1531/4885LCK 4400/4885CRBN 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.